| __timestamp | PTC Therapeutics, Inc. | United Therapeutics Corporation |
|---|---|---|
| Wednesday, January 1, 2014 | 79838000 | 125883000 |
| Thursday, January 1, 2015 | 121816000 | 69036000 |
| Friday, January 1, 2016 | 117633000 | 72700000 |
| Sunday, January 1, 2017 | 4577000 | 105700000 |
| Monday, January 1, 2018 | 12670000 | 198700000 |
| Tuesday, January 1, 2019 | 12135000 | 117600000 |
| Wednesday, January 1, 2020 | 18942000 | 108100000 |
| Friday, January 1, 2021 | 32328000 | 122500000 |
| Saturday, January 1, 2022 | 44678000 | 146700000 |
| Sunday, January 1, 2023 | 65486000 | 257500000 |
Unveiling the hidden dimensions of data
In the dynamic world of biotechnology, understanding cost structures is crucial for investors and stakeholders. This analysis delves into the cost of revenue trends for United Therapeutics Corporation and PTC Therapeutics, Inc. over the past decade. From 2014 to 2023, United Therapeutics consistently outpaced PTC Therapeutics, with costs peaking at approximately 258% higher in 2023 compared to 2014. Meanwhile, PTC Therapeutics saw a more volatile trajectory, with a significant dip in 2017, where costs plummeted to just 4% of their 2015 peak. By 2023, PTC's costs rebounded to nearly 82% of United Therapeutics' costs in 2014. This data highlights the contrasting financial strategies and market responses of these two industry leaders. As the biotech sector continues to evolve, monitoring these trends offers valuable insights into operational efficiencies and market positioning.
Cost of Revenue Trends: Pfizer Inc. vs PTC Therapeutics, Inc.
Cost of Revenue: Key Insights for Vertex Pharmaceuticals Incorporated and United Therapeutics Corporation
Cost of Revenue: Key Insights for Zoetis Inc. and PTC Therapeutics, Inc.
Analyzing Cost of Revenue: United Therapeutics Corporation and Neurocrine Biosciences, Inc.
United Therapeutics Corporation vs Sarepta Therapeutics, Inc.: Efficiency in Cost of Revenue Explored
Breaking Down SG&A Expenses: United Therapeutics Corporation vs PTC Therapeutics, Inc.
Cost of Revenue Trends: United Therapeutics Corporation vs HUTCHMED (China) Limited
Cost of Revenue: Key Insights for Halozyme Therapeutics, Inc. and PTC Therapeutics, Inc.
Cost Insights: Breaking Down PTC Therapeutics, Inc. and Perrigo Company plc's Expenses
PTC Therapeutics, Inc. vs HUTCHMED (China) Limited: Efficiency in Cost of Revenue Explored
Cost of Revenue: Key Insights for PTC Therapeutics, Inc. and Dyne Therapeutics, Inc.